1. 792OA randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC). (23rd October 2018) Authors: Chi, K N; Taavitsainen, S; Iqbal, N; Ferrario, C; Ong, M; Wadhwa, D; Hotte, S J; Lo, G; Tran, B; Azad, A; Wood, L; Gingerich, J R; North, S; Pezaro, C V; Ruether, D; Sridhar, S S; Annala, M; Bacon, J; Wyatt, A W Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A74 SURVEILLANCE IMAGING FOLLOWING COMPLETELY RESECTED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS: A SINGLE CENTER AUDIT OF LOCAL PRACTICE PATTERNS. (21st February 2022) Authors: Iannuzzi, J; Yeo, C; Sawhnry, S; Pasieka, J; Parkins, V; Ruether, D; Chan, D; Albalawi, Z; Lithgow, K Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 5(2022)Supplement 1 Page Start: 85 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗